Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.

Noninvasive diagnostic tests for NAFLD: Accuracy without the agony

08 Sep 2020
Non-alcoholic fatty liver disease (NAFLD) is characterized by steatosis, liver cell injury and inflammation. It is rapidly becoming the most common liver disease worldwide. Its prevalence in Asia is increasing which is attributed to the increased metabolic risk factors including obesity, diabetes and metabolic syndrome. In a Sanofi-sponsored symposium during the Philippine Liver Meeting of The Hepatology Society of the Philippines at the EDSA Shangri-la Hotel, Mandaluyong City on 22 January 2020, Dr Jose Sollano Jr., Gastroenterologist at the Asian Hospital and Medical Center, explored the diagnostic approach to assess the severity of NAFLD and discussed the available noninvasive diagnostic tests to assess patients suspected with NAFLD.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.